Marine Biotech Revenues Projected to Reach $3.78 Billion by 2012, According to New Report by Global Industry Analysts, Inc.

Share Article

Driven by growing interest from the medical, pharmaceutical, aquaculture, nutraceutical and industrial sectors, the global market for marine biotechnology is projected to reach a value of US$3.78 billion by 2012.

Marine Biotechnology: A Global Strategic Business Report

Comprising the largest part of the planet's biosphere, the marine environment contains the most diverse and ancient forms of life. The advent of advanced scientific disciplines such as molecular biology, genomics, bioinformatics and application of information technology to biotechnology, has tremendously enhanced human understanding of marine life. Widening applications in several end-use areas including marine transportation, environmental remediation, cosmetics, research, and food sectors also contributed to market growth. However, the industry is still in a nascent stage and accounts for a tiny percentage of the overall biotech market. Given the vast untapped potential, the marine biotech sector holds promising growth prospects for the future.

United States is the single largest market for marine biotechnology worldwide. The market is forecast to be over US$1 billion in 2008 as stated by Global Industry Analysts, Inc. Non-US markets are projected to record faster growth with a compounded annual rate exceeding 5% through 2012. Biomaterials represent the largest segment with a 50% share. Thickeners including agar, alginates, and carrageen, and flocculents comprising mainly of chitosan, account for a majority of the marine biomaterials market. Bioactive substances represent the second-largest segment generating sales of US$1.44 billion.

The marine biotech sector is characterized by the presence of numerous players ranging from pharmaceutical companies to research-oriented niche companies. Market participants include Aker BioMarine ASA, CP Kelco US Inc, Cyanotech Corp, Elan Corp, FMC Corp, FMC Biopolymers AS, GlycoMar Ltd, Integrin Advanced Biosystems, International Specialty Products Inc, Lonza Group Ltd, MariCal, Marinova, Martek Biosciences Corp, Mera Pharmaceuticals Inc, New England Biolabs Inc, PharmaMar S.A, PML Applications Ltd, Primex Ltd, Prolume Ltd, Sea Run Holdings Inc and Tequesta Marine Biosciences.

"Marine Biotechnology: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of market trends, drivers, product/technology profile, players, end-use analysis, recent developments, mergers, acquisitions, and other strategic industry activities. Analysis is presented for major geographic markets including United States and rest of world. Analytics are provided in terms of product segments including Marine Biomaterials, Marine Bioactive Substances, and Others. The study also covers end-use analytics for Industrial Products, Health Care/Biotechnology, Consumer Products, Public Services and Infrastructure sectors.

For more details about this research report, please visit http://www.strategyr.com/Marine_Biotechnology_Market_Report.asp.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press@StrategyR.com
Web Site http://www.StrategyR.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website